Markets

MAIA Biotechnology Says First US Patient Dosed In Phase 2 THIO-101 Trial Expansion Evaluating Telomere-Targeting Lead Candidate, Ateganosine, In Third-Line Non-Small Cell Lung Cancer

Sep 16, 2026 · 08:16 AM ET· updated 1h ago

Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies U.S. expansion is funded by a $2.3 million NIH grant to MAIA

Why It Matters

MAIA got permission to test its cancer medicine on more US patients. The company received money and showed it can make the drug better.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MAIA1.36

+0.01 (+1.12%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.